 Thomas Attard
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenomatous Polyposis Coli | 17 | 2022 | 24 | 5.370 |
Why?
| | Child | 47 | 2022 | 2874 | 2.780 |
Why?
| | Humans | 62 | 2022 | 6128 | 2.690 |
Why?
| | Gastrointestinal Hemorrhage | 5 | 2020 | 15 | 2.250 |
Why?
| | Adolescent | 31 | 2022 | 1976 | 2.180 |
Why?
| | Child, Preschool | 27 | 2022 | 1459 | 1.950 |
Why?
| | Endoscopy, Gastrointestinal | 4 | 2018 | 20 | 1.940 |
Why?
| | Male | 35 | 2022 | 3284 | 1.920 |
Why?
| | Female | 34 | 2022 | 3367 | 1.800 |
Why?
| | Foreign Bodies | 3 | 2021 | 23 | 1.790 |
Why?
| | Inpatients | 3 | 2022 | 51 | 1.780 |
Why?
| | Endoscopy | 4 | 2020 | 15 | 1.640 |
Why?
| | Pediatrics | 5 | 2020 | 175 | 1.600 |
Why?
| | Colonoscopy | 9 | 2019 | 12 | 1.580 |
Why?
| | Retrospective Studies | 17 | 2022 | 1196 | 1.470 |
Why?
| | Emergency Service, Hospital | 3 | 2019 | 123 | 1.460 |
Why?
| | Intestinal Polyposis | 4 | 2019 | 5 | 1.400 |
Why?
| | Mutation | 9 | 2019 | 202 | 1.370 |
Why?
| | Infant | 17 | 2022 | 1399 | 1.330 |
Why?
| | Genetic Counseling | 4 | 2016 | 7 | 1.200 |
Why?
| | Microbiota | 2 | 2022 | 9 | 1.200 |
Why?
| | United States | 8 | 2022 | 640 | 1.180 |
Why?
| | Adenomatous Polyposis Coli Protein | 3 | 2018 | 6 | 1.130 |
Why?
| | Neoplastic Syndromes, Hereditary | 3 | 2019 | 4 | 1.100 |
Why?
| | Colonic Polyps | 2 | 2019 | 3 | 1.060 |
Why?
| | Cohort Studies | 7 | 2022 | 256 | 1.050 |
Why?
| | Databases, Factual | 6 | 2022 | 107 | 1.020 |
Why?
| | Fractures, Bone | 2 | 2022 | 34 | 1.020 |
Why?
| | Polyps | 3 | 2013 | 4 | 1.000 |
Why?
| | Consensus | 4 | 2021 | 29 | 0.990 |
Why?
| | Adult | 12 | 2021 | 1107 | 0.980 |
Why?
| | Hospitalization | 3 | 2022 | 179 | 0.980 |
Why?
| | Gastrointestinal Neoplasms | 5 | 2019 | 7 | 0.960 |
Why?
| | Colonic Neoplasms | 1 | 2022 | 7 | 0.950 |
Why?
| | Malnutrition | 1 | 2022 | 11 | 0.930 |
Why?
| | Histamine H2 Antagonists | 1 | 2022 | 8 | 0.920 |
Why?
| | Colorectal Neoplasms | 3 | 2019 | 15 | 0.920 |
Why?
| | Histamine | 1 | 2022 | 11 | 0.910 |
Why?
| | Peutz-Jeghers Syndrome | 4 | 2019 | 6 | 0.890 |
Why?
| | Electronic Health Records | 1 | 2022 | 57 | 0.880 |
Why?
| | Patient Transfer | 1 | 2021 | 7 | 0.870 |
Why?
| | Quality of Life | 1 | 2022 | 116 | 0.860 |
Why?
| | Disease Management | 1 | 2021 | 36 | 0.850 |
Why?
| | Societies, Medical | 1 | 2021 | 44 | 0.850 |
Why?
| | Young Adult | 7 | 2019 | 594 | 0.820 |
Why?
| | Proton Pump Inhibitors | 1 | 2020 | 13 | 0.810 |
Why?
| | Autism Spectrum Disorder | 1 | 2020 | 23 | 0.800 |
Why?
| | Orthodontic Wires | 1 | 2019 | 1 | 0.800 |
Why?
| | Orthodontics | 1 | 2019 | 1 | 0.800 |
Why?
| | Self-Injurious Behavior | 1 | 2019 | 2 | 0.800 |
Why?
| | Endoscopy, Digestive System | 2 | 2018 | 8 | 0.790 |
Why?
| | Capsule Endoscopy | 2 | 2019 | 3 | 0.790 |
Why?
| | Biomass | 2 | 2018 | 2 | 0.770 |
Why?
| | Cholecystitis | 1 | 2019 | 6 | 0.770 |
Why?
| | Cathartics | 1 | 2018 | 4 | 0.740 |
Why?
| | Hospitals, Pediatric | 2 | 2019 | 179 | 0.740 |
Why?
| | Polyethylene Glycols | 1 | 2018 | 12 | 0.730 |
Why?
| | Gastrostomy | 1 | 2019 | 69 | 0.730 |
Why?
| | Genetic Predisposition to Disease | 6 | 2015 | 144 | 0.730 |
Why?
| | Postoperative Complications | 1 | 2019 | 179 | 0.670 |
Why?
| | Genetic Testing | 6 | 2019 | 74 | 0.640 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 5 | 0.630 |
Why?
| | Risk Factors | 5 | 2020 | 393 | 0.620 |
Why?
| | Age Distribution | 4 | 2019 | 32 | 0.620 |
Why?
| | Patient Readmission | 1 | 2017 | 70 | 0.620 |
Why?
| | Length of Stay | 4 | 2022 | 237 | 0.600 |
Why?
| | Intestinal Polyps | 3 | 2019 | 3 | 0.600 |
Why?
| | Zea mays | 1 | 2015 | 1 | 0.590 |
Why?
| | Waxes | 1 | 2015 | 1 | 0.590 |
Why?
| | Pedigree | 6 | 2019 | 52 | 0.590 |
Why?
| | Carbon Dioxide | 1 | 2015 | 17 | 0.590 |
Why?
| | Treatment Outcome | 6 | 2019 | 624 | 0.580 |
Why?
| | Biopsy | 4 | 2022 | 54 | 0.530 |
Why?
| | Internship and Residency | 2 | 2015 | 28 | 0.510 |
Why?
| | Barrett Esophagus | 1 | 2013 | 1 | 0.500 |
Why?
| | Esophageal Diseases | 1 | 2013 | 1 | 0.500 |
Why?
| | Esophagitis | 1 | 2013 | 7 | 0.500 |
Why?
| | Age Factors | 4 | 2018 | 220 | 0.500 |
Why?
| | Collagen | 1 | 2013 | 4 | 0.500 |
Why?
| | Gastritis | 1 | 2013 | 8 | 0.500 |
Why?
| | Stomach | 1 | 2013 | 15 | 0.490 |
Why?
| | Esophagus | 1 | 2013 | 32 | 0.490 |
Why?
| | Genes, APC | 2 | 2015 | 3 | 0.470 |
Why?
| | Stomach Neoplasms | 2 | 2002 | 4 | 0.450 |
Why?
| | Elective Surgical Procedures | 3 | 2020 | 14 | 0.450 |
Why?
| | Appointments and Schedules | 2 | 2020 | 13 | 0.410 |
Why?
| | Celiac Disease | 3 | 2017 | 4 | 0.410 |
Why?
| | Coronavirus Infections | 2 | 2020 | 16 | 0.410 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 17 | 0.400 |
Why?
| | Duodenal Neoplasms | 2 | 2016 | 2 | 0.400 |
Why?
| | Digestive System Surgical Procedures | 2 | 2020 | 45 | 0.390 |
Why?
| | Crohn Disease | 2 | 2011 | 21 | 0.370 |
Why?
| | Gastrointestinal Diseases | 2 | 2020 | 55 | 0.370 |
Why?
| | Clinical Competence | 1 | 2009 | 37 | 0.360 |
Why?
| | Mass Screening | 2 | 2019 | 42 | 0.360 |
Why?
| | Recurrence | 2 | 2019 | 106 | 0.350 |
Why?
| | Acute Disease | 2 | 2019 | 65 | 0.350 |
Why?
| | Colectomy | 4 | 2016 | 10 | 0.350 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 5 | 0.350 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 4 | 0.350 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2009 | 81 | 0.350 |
Why?
| | Comorbidity | 2 | 2019 | 67 | 0.350 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2007 | 2 | 0.350 |
Why?
| | Molecular Biology | 1 | 2007 | 3 | 0.350 |
Why?
| | Genetics, Population | 1 | 2007 | 9 | 0.320 |
Why?
| | Time Factors | 2 | 2019 | 273 | 0.320 |
Why?
| | Prevalence | 3 | 2022 | 137 | 0.320 |
Why?
| | Brain Neoplasms | 1 | 2007 | 32 | 0.320 |
Why?
| | Syndrome | 2 | 2021 | 30 | 0.310 |
Why?
| | Chronic Disease | 2 | 2019 | 111 | 0.300 |
Why?
| | Fibromatosis, Aggressive | 2 | 2016 | 3 | 0.300 |
Why?
| | Risk Assessment | 3 | 2019 | 132 | 0.290 |
Why?
| | Neoplasms | 2 | 2019 | 96 | 0.280 |
Why?
| | Abdominal Pain | 2 | 2018 | 71 | 0.280 |
Why?
| | Prognosis | 4 | 2007 | 179 | 0.270 |
Why?
| | Ileitis | 1 | 2004 | 3 | 0.270 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 97 | 0.270 |
Why?
| | Jejunal Diseases | 1 | 2004 | 3 | 0.270 |
Why?
| | Nutritional Support | 1 | 2004 | 4 | 0.270 |
Why?
| | Eating | 2 | 2021 | 31 | 0.260 |
Why?
| | Intussusception | 2 | 2019 | 15 | 0.250 |
Why?
| | Patient Selection | 2 | 2020 | 46 | 0.250 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2003 | 1 | 0.250 |
Why?
| | Hamartoma | 1 | 2003 | 4 | 0.250 |
Why?
| | Pandemics | 2 | 2020 | 65 | 0.250 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 8 | 0.240 |
Why?
| | Gastroenterology | 2 | 2019 | 15 | 0.240 |
Why?
| | Ileum | 2 | 2019 | 22 | 0.240 |
Why?
| | Sex Distribution | 2 | 2018 | 18 | 0.240 |
Why?
| | Health Care Surveys | 2 | 2015 | 34 | 0.240 |
Why?
| | Longitudinal Studies | 1 | 2022 | 131 | 0.230 |
Why?
| | Hospitals | 1 | 2022 | 37 | 0.230 |
Why?
| | Enterobacteriaceae Infections | 1 | 2021 | 8 | 0.230 |
Why?
| | Stem Cells | 1 | 2021 | 20 | 0.230 |
Why?
| | Electric Power Supplies | 1 | 2021 | 4 | 0.230 |
Why?
| | Colitis | 1 | 2021 | 9 | 0.230 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 45 | 0.230 |
Why?
| | Diet | 1 | 2021 | 52 | 0.220 |
Why?
| | Adenomatous Polyps | 1 | 2001 | 1 | 0.220 |
Why?
| | Adenocarcinoma | 1 | 2001 | 6 | 0.220 |
Why?
| | Algorithms | 4 | 2021 | 98 | 0.210 |
Why?
| | Meckel Diverticulum | 1 | 2020 | 8 | 0.210 |
Why?
| | Phenotype | 3 | 2013 | 222 | 0.210 |
Why?
| | Digestive System | 1 | 2020 | 1 | 0.210 |
Why?
| | Appendix | 1 | 2000 | 11 | 0.210 |
Why?
| | Ileal Diseases | 1 | 2000 | 8 | 0.210 |
Why?
| | Hepatoblastoma | 2 | 2019 | 7 | 0.210 |
Why?
| | Communicable Disease Control | 1 | 2020 | 7 | 0.210 |
Why?
| | Cystic Fibrosis | 1 | 2000 | 16 | 0.210 |
Why?
| | Odds Ratio | 1 | 2020 | 47 | 0.200 |
Why?
| | Bioethical Issues | 1 | 2019 | 3 | 0.200 |
Why?
| | Personal Autonomy | 1 | 2019 | 4 | 0.200 |
Why?
| | Laparoscopy | 2 | 2020 | 242 | 0.200 |
Why?
| | Secondary Prevention | 1 | 2019 | 7 | 0.200 |
Why?
| | Mortality | 1 | 2019 | 3 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 22 | 0.200 |
Why?
| | Disease Progression | 1 | 2019 | 93 | 0.190 |
Why?
| | Duodenum | 1 | 2019 | 21 | 0.190 |
Why?
| | Enteral Nutrition | 1 | 2019 | 55 | 0.190 |
Why?
| | Chlorine | 1 | 2018 | 1 | 0.180 |
Why?
| | Steam | 1 | 2018 | 1 | 0.180 |
Why?
| | Phenol | 1 | 2018 | 1 | 0.180 |
Why?
| | Soot | 1 | 2018 | 1 | 0.180 |
Why?
| | Waste Water | 1 | 2018 | 1 | 0.180 |
Why?
| | Laxatives | 1 | 2018 | 5 | 0.180 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 40 | 0.180 |
Why?
| | Hospital Charges | 1 | 2018 | 12 | 0.180 |
Why?
| | Social Class | 1 | 2018 | 9 | 0.180 |
Why?
| | Administration, Oral | 1 | 2018 | 63 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 87 | 0.180 |
Why?
| | Infant, Newborn | 2 | 2019 | 887 | 0.180 |
Why?
| | Patient Discharge | 1 | 2019 | 59 | 0.180 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 9 | 0.180 |
Why?
| | Gastric Mucosa | 2 | 2013 | 14 | 0.180 |
Why?
| | Fever | 1 | 2018 | 27 | 0.180 |
Why?
| | Hypercalcemia | 1 | 1998 | 10 | 0.180 |
Why?
| | Mandibular Neoplasms | 1 | 2018 | 2 | 0.180 |
Why?
| | Osteoma | 1 | 2018 | 2 | 0.180 |
Why?
| | Osteosclerosis | 1 | 2018 | 2 | 0.180 |
Why?
| | Dentofacial Deformities | 1 | 2018 | 2 | 0.180 |
Why?
| | Sex Factors | 1 | 2018 | 77 | 0.180 |
Why?
| | Urban Population | 1 | 2018 | 34 | 0.180 |
Why?
| | Liver Diseases | 1 | 1998 | 10 | 0.180 |
Why?
| | Diphosphonates | 1 | 1998 | 12 | 0.180 |
Why?
| | Rural Population | 1 | 2018 | 31 | 0.180 |
Why?
| | Aged | 3 | 2020 | 304 | 0.170 |
Why?
| | Double-Balloon Enteroscopy | 1 | 2017 | 1 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2018 | 40 | 0.170 |
Why?
| | Genotyping Techniques | 2 | 2017 | 18 | 0.170 |
Why?
| | Patient Compliance | 1 | 2018 | 73 | 0.170 |
Why?
| | Liver Transplantation | 1 | 1998 | 38 | 0.170 |
Why?
| | African Americans | 1 | 2018 | 109 | 0.170 |
Why?
| | Patient Admission | 1 | 2017 | 9 | 0.160 |
Why?
| | Diarrhea, Infantile | 1 | 2017 | 3 | 0.160 |
Why?
| | Multivariate Analysis | 1 | 2017 | 72 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2016 | 13 | 0.160 |
Why?
| | Vomiting | 2 | 2014 | 22 | 0.160 |
Why?
| | Thyroid Neoplasms | 1 | 2016 | 1 | 0.160 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2016 | 2 | 0.160 |
Why?
| | Chemoprevention | 1 | 2016 | 4 | 0.160 |
Why?
| | Guideline Adherence | 1 | 2017 | 34 | 0.160 |
Why?
| | Intestinal Mucosa | 1 | 2017 | 36 | 0.160 |
Why?
| | Electronic Mail | 1 | 2015 | 2 | 0.150 |
Why?
| | Canada | 1 | 2015 | 33 | 0.150 |
Why?
| | Needs Assessment | 1 | 2015 | 21 | 0.150 |
Why?
| | Curriculum | 1 | 2015 | 17 | 0.150 |
Why?
| | Plant Leaves | 1 | 2015 | 2 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2015 | 17 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 37 | 0.140 |
Why?
| | Evidence-Based Medicine | 3 | 2019 | 44 | 0.140 |
Why?
| | Registries | 2 | 2007 | 80 | 0.140 |
Why?
| | Biopsy, Needle | 2 | 2006 | 3 | 0.130 |
Why?
| | Serologic Tests | 1 | 2014 | 6 | 0.130 |
Why?
| | Intestine, Small | 1 | 2014 | 17 | 0.130 |
Why?
| | Deglutition Disorders | 1 | 2013 | 2 | 0.130 |
Why?
| | Failure to Thrive | 1 | 2013 | 7 | 0.120 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2013 | 5 | 0.120 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2013 | 1 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 42 | 0.120 |
Why?
| | Chromosome Deletion | 1 | 2013 | 14 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 103 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2017 | 308 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2020 | 115 | 0.120 |
Why?
| | Dyspepsia | 1 | 2013 | 49 | 0.120 |
Why?
| | Prospective Studies | 3 | 2019 | 475 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2019 | 150 | 0.110 |
Why?
| | Mediterranean Region | 3 | 2017 | 3 | 0.100 |
Why?
| | Radiography, Panoramic | 2 | 2021 | 3 | 0.100 |
Why?
| | Phenylhydrazines | 1 | 2009 | 1 | 0.100 |
Why?
| | Mesalamine | 1 | 2009 | 1 | 0.100 |
Why?
| | Colitis, Ulcerative | 1 | 2009 | 7 | 0.100 |
Why?
| | Colon | 1 | 2009 | 13 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 12 | 0.100 |
Why?
| | Internet | 1 | 2009 | 17 | 0.090 |
Why?
| | Germ-Line Mutation | 1 | 2007 | 5 | 0.090 |
Why?
| | DNA Mutational Analysis | 1 | 2007 | 45 | 0.090 |
Why?
| | Codon | 1 | 2007 | 3 | 0.080 |
Why?
| | Asia | 1 | 2007 | 9 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 281 | 0.080 |
Why?
| | Europe | 1 | 2007 | 30 | 0.080 |
Why?
| | North America | 1 | 2007 | 44 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 286 | 0.080 |
Why?
| | Genotype | 1 | 2007 | 298 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2006 | 71 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2006 | 23 | 0.070 |
Why?
| | Transglutaminases | 2 | 2017 | 3 | 0.070 |
Why?
| | GTP-Binding Proteins | 2 | 2017 | 7 | 0.070 |
Why?
| | HLA Antigens | 2 | 2017 | 12 | 0.070 |
Why?
| | Precancerous Conditions | 1 | 2004 | 4 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2004 | 186 | 0.060 |
Why?
| | Gastroscopy | 1 | 2002 | 1 | 0.060 |
Why?
| | Maryland | 1 | 2002 | 3 | 0.060 |
Why?
| | Fermentation | 1 | 2021 | 2 | 0.060 |
Why?
| | Pectins | 1 | 2021 | 2 | 0.060 |
Why?
| | Biodiversity | 1 | 2021 | 2 | 0.060 |
Why?
| | Mucin-2 | 1 | 2021 | 2 | 0.060 |
Why?
| | Epithelium | 1 | 2021 | 6 | 0.060 |
Why?
| | Regeneration | 1 | 2021 | 3 | 0.060 |
Why?
| | Butyrates | 1 | 2021 | 3 | 0.060 |
Why?
| | Citrobacter rodentium | 1 | 2021 | 4 | 0.060 |
Why?
| | HEK293 Cells | 1 | 2021 | 32 | 0.060 |
Why?
| | Triglycerides | 1 | 2021 | 21 | 0.060 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 15 | 0.060 |
Why?
| | Middle Aged | 1 | 2004 | 557 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 58 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2021 | 70 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2021 | 85 | 0.060 |
Why?
| | Incidence | 1 | 2002 | 131 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 130 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 102 | 0.050 |
Why?
| | Gastrectomy | 1 | 2001 | 1 | 0.050 |
Why?
| | Gastric Fundus | 1 | 2001 | 2 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 140 | 0.050 |
Why?
| | Triage | 1 | 2020 | 5 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2000 | 16 | 0.050 |
Why?
| | Cecum | 1 | 2000 | 5 | 0.050 |
Why?
| | Symptom Assessment | 1 | 2020 | 12 | 0.050 |
Why?
| | Radiography | 1 | 2000 | 37 | 0.050 |
Why?
| | Gastrointestinal Transit | 1 | 2020 | 1 | 0.050 |
Why?
| | Adenoma | 1 | 2019 | 4 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2019 | 9 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2019 | 24 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 8 | 0.050 |
Why?
| | Animals | 1 | 2021 | 896 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 144 | 0.050 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 102 | 0.040 |
Why?
| | Osteoclasts | 1 | 1998 | 3 | 0.040 |
Why?
| | Jaw | 1 | 2018 | 2 | 0.040 |
Why?
| | Parenteral Nutrition, Total | 1 | 1998 | 7 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2018 | 130 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2017 | 61 | 0.040 |
Why?
| | Connective Tissue | 1 | 2017 | 2 | 0.040 |
Why?
| | Autoantibodies | 1 | 2017 | 8 | 0.040 |
Why?
| | Health Resources | 1 | 2017 | 17 | 0.040 |
Why?
| | Self Report | 1 | 2016 | 41 | 0.040 |
Why?
| | Intestines | 1 | 2017 | 26 | 0.040 |
Why?
| | Africa, Northern | 1 | 2014 | 1 | 0.030 |
Why?
| | Europe, Eastern | 1 | 2014 | 1 | 0.030 |
Why?
| | Anorexia | 1 | 2014 | 2 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 15 | 0.030 |
Why?
| | Diarrhea | 1 | 2014 | 16 | 0.030 |
Why?
| | Haplotypes | 1 | 2014 | 54 | 0.030 |
Why?
| | Weight Loss | 1 | 2014 | 41 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2013 | 2 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2013 | 2 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 7 | 0.030 |
Why?
| | Health Care Costs | 1 | 2011 | 32 | 0.030 |
Why?
| | Aminosalicylic Acids | 1 | 2009 | 1 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2009 | 50 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|